Singapore markets closed

LLY Jan 2025 165.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.42000.0000 (0.00%)
As of 03:52PM EDT. Market open.
Full screen
Previous close0.4200
Expiry date2025-01-17
Day's range0.4200 - 0.4200
Contract rangeN/A
Open interest15

    Obesity treatment optimism boosts Eli Lilly, Novo Nordisk while others face downturn

    Pharmaceutical majors Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) have experienced a significant increase in their market value on Thursday, driven by the potential of their weight-loss drugs, GLP-1s, to address the global obesity epidemic. This optimism has propelled sales forecasts into the hundreds of billions. However, this same optimism has negatively impacted companies that have traditionally profited from treating obesity-related complications.


    Obesity drugs by Novo Nordisk and Eli Lilly to impact healthcare economy

    Leading pharmaceutical companies, Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), are anticipated to see significant revenue growth from their newly developed obesity drugs, according to financial analysts' predictions. These medications, known as GLP-1 receptor agonists, are considered the safest and most effective weight-loss drugs currently available. They offer potential body weight reductions of up to 20% and could also diminish patients' risk of heart attack or stroke.

  • Motley Fool

    3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 Years

    You don't have to invest in artificial intelligence or the latest tech company to earn great returns on your investments. The healthcare industry is full of promising investment opportunities of its own. DexCom (NASDAQ: DXCM), Eli Lilly (NYSE: LLY), and West Pharmaceutical Services (NYSE: WST) are three stocks that have each turned $100,000 investments into $1 million over the past 10 years.